为了获得访问"阿拉丁铁蛋"实时聊天框的流畅支持体验,建议您使用Chrome浏览器或选择360浏览器极速模式(如何切换极速模式?),感谢您选择我们!

伯舒替尼 (SKI-606), 酪氨酸蛋白激酶 Lyn 抑制剂

双重Src-Abl抑制剂; 抗增殖
规格或纯度: ≥99%
有货

库存信息

关闭

库存信息

关闭

库存信息

关闭

库存信息

关闭

库存信息

关闭
货号 (SKU) 包装规格 是否现货 价格 数量
B129905-10mg
10mg 现货 Stock Image
B129905-50mg
50mg 现货 Stock Image
B129905-100mg
100mg 现货 Stock Image
B129905-250mg
250mg 期货 Stock Image
B129905-1g
1g 期货 Stock Image

基本描述

别名 伯舒替尼
英文别名 SKI-606|WAY-173606|Bosutinib,SKI-606|BSPBio_001023|NCGC00241107-03|NSC799367|NSC-799367|4-(2,4-Dichloro-5-methoxy-phenylamino)-6-methoxy-7-[3-(4-methyl-piperazin-1-yl)propoxy]quinoline-3-carbonitrile|5018V4AEZ0|DB06616|SK 606|2-[4-(2,3-dihydro-1,4-benzodi
规格或纯度 ≥99%
英文名称 Bosutinib (SKI-606)
生化机理 Abl和Src激酶的双重抑制剂(在酶法测定中,Src的IC50 = 1.2 nM)。对慢性骨髓性白血病(CML)细胞显示抗增殖活性,并降低乳腺癌细胞系的运动性和侵袭性。在不依赖于锚定的Src转化的大鼠成纤维细胞(IC50 = 100 nM)中也表现出有效的抗增殖活性。与非Src家族激酶(例如生长因子受体酪氨酸激酶)相比,显示Src的选择性。
法律信息 Sold for research purposes under agreement from Pfizer Inc. - Not for human or veterinary use.
运输条件 常规运输
产品介绍

Bosutinib (SKI-606) is a potent c-Abl, Bcr-Abl, and Src-Abl kinase inhibitor, shown to effectively interfere with the progress of chronic myelogenous leukemia (CML). In a competitive study with Imatinib, Bosutinib was shown to inhibit Bcr-Abl kinase activity in CD34+ CML cells more potently than Imatinib. Activity of Src-Abl has been implicated in the development of other non-CML malignancies, and Bosutinib has demonstrated in studies to suppress breast cancer growth and migration.A c-Abl, Src-Abl, and Bcr-Abl inhibitor

Bosutinib (SKI-606) is a potent c-Abl, Bcr-Abl, and Src-Abl kinase inhibitor, shown to effectively interfere with the progress of chronic myelogenous leukemia (CML). In a competitive study with Imatinib, Bosutinib was shown to inhibit Bcr-Abl kinase activity in CD34+ CML cells more potently than Imatinib. Activity of Src-Abl has been implicated in the development of other non-CML malignancies, and Bosutinib has demonstrated in studies to suppress breast cancer growth and migration.
A c-Abl, Src-Abl, and Bcr-Abl inhibitor

产品属性

ALogP 5.4

名称和标识符

IUPAC Name 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile
INCHI InChI=1S/C26H29Cl2N5O3/c1-32-6-8-33(9-7-32)5-4-10-36-25-13-21-18(11-24(25)35-3)26(17(15-29)16-30-21)31-22-14-23(34-2)20(28)12-19(22)27/h11-14,16H,4-10H2,1-3H3,(H,30,31)
InChi Key UBPYILGKFZZVDX-UHFFFAOYSA-N
Canonical SMILES CN1CCN(CC1)CCCOC2=C(C=C3C(=C2)N=CC(=C3NC4=CC(=C(C=C4Cl)Cl)OC)C#N)OC
Isomeric SMILES CN1CCN(CC1)CCCOC2=C(C=C3C(=C2)N=CC(=C3NC4=CC(=C(C=C4Cl)Cl)OC)C#N)OC
WGK Germany 3
PubChem CID 5328940
分子量 530.45

化学和物理性质

溶解性 溶于DMSO, 最高浓度 (mg/mL): 53.05, 最高浓度(mM): 100;溶于ethanol, 最高浓度 (mg/mL): 13.26, 最高浓度(mM): 25

安全和危险性(GHS)

象形图
ghs07

Harmful

危险声明 H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
预防措施声明 P261,P305+P351+P338
WGK Germany 3

质检证书(COA)

质检报告(COA)

输入批号以搜索COA:

产品问答

产品问答

登录提交问题 Hover me 请先登录再提交问题
您提交该产品问题后,我们会在1-2个工作日内给您答复,您可以登录"我的账号",然后点击"我的产品问答"查看答案

参考文献

1. Puttini M, Coluccia AM, Boschelli F, Cleris L, Marchesi E, Donella-Deana A, Ahmed S, Redaelli S, Piazza R, Magistroni V et al..  (2006)  In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells..  Cancer Res,  66  (23):  (11314-22).  [PMID:17114238]
2. Remsing Rix LL, Rix U, Colinge J, Hantschel O, Bennett KL, Stranzl T, Müller A, Baumgartner C, Valent P, Augustin M et al..  (2009)  Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells..  Leukemia,  23  (3):  (477-85).  [PMID:19039322]
3. Ozanne J, Prescott AR, Clark K.  (2015)  The clinically approved drugs dasatinib and bosutinib induce anti-inflammatory macrophages by inhibiting the salt-inducible kinases..  Biochem J,  465  (2):  (271-9).  [PMID:25351958]